Zhejiang Jiuzhou Pharmaceutical Co., Ltd

SHSE:603456 Stock Report

Market Cap: CN¥12.3b

Zhejiang Jiuzhou Pharmaceutical Past Earnings Performance

Past criteria checks 2/6

Zhejiang Jiuzhou Pharmaceutical has been growing earnings at an average annual rate of 35.5%, while the Pharmaceuticals industry saw earnings growing at 9.2% annually. Revenues have been growing at an average rate of 25.4% per year. Zhejiang Jiuzhou Pharmaceutical's return on equity is 11.3%, and it has net margins of 18.9%.

Key information

35.5%

Earnings growth rate

33.6%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate25.4%
Return on equity11.3%
Net Margin18.9%
Next Earnings Update27 Aug 2024

Recent past performance updates

Zhejiang Jiuzhou Pharmaceutical's (SHSE:603456) Solid Earnings May Rest On Weak Foundations

May 01
Zhejiang Jiuzhou Pharmaceutical's (SHSE:603456) Solid Earnings May Rest On Weak Foundations

Recent updates

Here's Why Zhejiang Jiuzhou Pharmaceutical (SHSE:603456) Can Manage Its Debt Responsibly

Jun 13
Here's Why Zhejiang Jiuzhou Pharmaceutical (SHSE:603456) Can Manage Its Debt Responsibly

Zhejiang Jiuzhou Pharmaceutical Co., Ltd's (SHSE:603456) Business And Shares Still Trailing The Market

May 24
Zhejiang Jiuzhou Pharmaceutical Co., Ltd's (SHSE:603456) Business And Shares Still Trailing The Market

Zhejiang Jiuzhou Pharmaceutical's (SHSE:603456) Solid Earnings May Rest On Weak Foundations

May 01
Zhejiang Jiuzhou Pharmaceutical's (SHSE:603456) Solid Earnings May Rest On Weak Foundations

Zhejiang Jiuzhou Pharmaceutical Co., Ltd Just Missed Revenue By 17%: Here's What Analysts Think Will Happen Next

Apr 11
Zhejiang Jiuzhou Pharmaceutical Co., Ltd Just Missed Revenue By 17%: Here's What Analysts Think Will Happen Next

Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHSE:603456) Shares Could Be 32% Above Their Intrinsic Value Estimate

Feb 28
Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHSE:603456) Shares Could Be 32% Above Their Intrinsic Value Estimate

Revenue & Expenses Breakdown

How Zhejiang Jiuzhou Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SHSE:603456 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 245,248989538317
31 Dec 235,5231,033544331
30 Sep 235,6491,145524300
30 Jun 235,7451,075510288
31 Mar 235,823994499302
31 Dec 225,445921474287
30 Sep 225,432904524279
30 Jun 225,150827516258
31 Mar 224,581747429202
31 Dec 214,063634391173
30 Sep 213,906614388160
30 Jun 213,507526332152
31 Mar 213,112443371132
31 Dec 202,647381347114
30 Sep 202,404341346105
30 Jun 202,16726537198
31 Mar 202,01022731796
31 Dec 192,01723828395
30 Sep 191,95219828391
30 Jun 191,80017127388
31 Mar 191,78514926689
31 Dec 181,86215728387
30 Sep 181,75212824281
30 Jun 181,839163199126
31 Mar 181,79815721699
31 Dec 171,71714822185
30 Sep 171,69613925265
30 Jun 171,6941473050
31 Mar 171,6971162970
31 Dec 161,6531112840
30 Sep 161,5591182480
30 Jun 161,5001262440
31 Mar 161,4581972530
31 Dec 151,4452002600
30 Sep 151,4321952700
30 Jun 151,3491702430
31 Mar 151,3251422090
31 Dec 141,2861331930
30 Sep 141,2291551670
31 Dec 131,3101661800

Quality Earnings: 603456 has a high level of non-cash earnings.

Growing Profit Margin: 603456's current net profit margins (18.9%) are higher than last year (17.1%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 603456's earnings have grown significantly by 35.5% per year over the past 5 years.

Accelerating Growth: 603456's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 603456 had negative earnings growth (-0.5%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-0.8%).


Return on Equity

High ROE: 603456's Return on Equity (11.3%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.